The partners will use Akoya's multiplex immunofluorescence platform for spatial phenotyping and JHU's AstroPath platform to identify predictive signatures.
Increased incidental detection of clonal hematopoiesis and new considerations for mutations in myelodysplastic precursors herald improved precision medicine strategies.
The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.
The new center will bring together pathology, computer science, cancer genomics, and immunogenomics to study which cancer patients can benefit from immunotherapy.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
